13 results match your criteria: "Health Research Board Stroke Clinical Trials Network Ireland[Affiliation]"

Background: Inflammation promotes atherogenesis. Randomized controlled trials of anti-inflammatory therapies for prevention after stroke have not yet demonstrated clear benefit. IL-6 (interleukin-6) and hsCRP (high-sensitivity C-reactive protein) are independently associated with major adverse cardiovascular events poststroke and may guide patient selection in future randomized controlled trials.

View Article and Find Full Text PDF

Background: Anti-inflammatory therapy with long-term colchicine prevented vascular recurrence in coronary disease. Unlike coronary disease, which is typically caused by atherosclerosis, ischaemic stroke is caused by diverse mechanisms including atherosclerosis and small vessel disease or is frequently due to an unknown cause. We aimed to investigate the hypothesis that long-term colchicine would reduce recurrent events after ischaemic stroke.

View Article and Find Full Text PDF

Atherosclerosis is a chronic systemic inflammatory condition of the vasculature and a leading cause of stroke. Luminal stenosis severity is an important factor in determining vascular risk. Conventional imaging modalities, such as angiography or duplex ultrasonography, are used to quantify stenosis severity and inform clinical care but provide limited information on plaque biology.

View Article and Find Full Text PDF

Background: For reasons poorly understood, strokes frequently occur in patients with atrial fibrillation (AF) despite oral anticoagulation. Better data are needed to inform randomised trials (RCTs) of new strategies to prevent recurrence in these patients. We investigate the relative contribution of competing stroke mechanisms in patients with AF who have stroke despite anticoagulation (OAC+) compared with those who are anticoagulant naïve (OAC-) at the time of their event.

View Article and Find Full Text PDF

Association of Plaque Inflammation With Stroke Recurrence in Patients With Unproven Benefit From Carotid Revascularization.

Neurology

July 2022

From the Stroke Unit (P.C.-R., J.M.-F., R.D.-M., M.G.-J., D.G.-A., A.M.-D., L.P.-S.), Department of Neurology, Institute of Biomedical Research Sant Pau (IIB-Sant Pau), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Health Research Board Stroke Clinical Trials Network Ireland (J.M., S.C., E.D., J.A.H., G.H., M.M., S.M., P.J.K.); Neurovascular Clinical Science Unit (J.M., G.H., M.M., S.M., P.J.K.), Stroke Service and Department of Neurology, Mater University Hospital/University College Dublin; Radiography & Diagnostic Imaging (N.G., J.P.M., S.F.), School of Medicine, University College Dublin, Ireland; Discipline of Medical Imaging Science (N.G.), School of Health Sciences, Faculty of Medicine and Health, University of Sydney, Australia; Department of Nuclear Medicine (A.F.-L.), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Department of Neurology (J.-C.B.), Université de Paris, Hopital Sainte-Anne, France; Department of Vascular Surgery (M.B.), St. Vincent's University Hospital and University College Dublin, Ireland; Departments of Clinical Neurosciences, Radiology, and Community Health Sciences (S.B.C.), University of Calgary, Alberta, Canada; Department of Neurology (S.C.), Cork University Hospital; Department of Clinical Neuroscience (S.C.), College of Medicine and Health, University College Cork, Ireland; Connolly Hospital Dublin and Royal College of Surgeons (E.D.); Stroke Service, Department of Geriatric Medicine (J.A.H.), St. James' Hospital and Trinity College; Departments of Radiology (E.C.K., M.O.C.) and Vascular Surgery (C.M.), Mater University Hospital and University College Dublin, Ireland; Division of Neurology (V.K.S.), National University Health System, and Yong Loo Lin School of Medicine, National University of Singapore; and Department of Geriatric and Stroke Medicine (D.W.), RCSI University of Medicine and Health Sciences/Beaumont Hospital, Dublin, Ireland.

Background And Objectives: In pooled analyses of endarterectomy trials for symptomatic carotid stenosis, several subgroups experienced no net benefit from revascularization. The validated symptomatic carotid atheroma inflammation lumen-stenosis (SCAIL) score includes stenosis severity and inflammation measured by PET and improves the identification of patients with recurrent stroke compared with lumen-stenosis alone. We investigated whether the SCAIL score improves the identification of recurrent stroke in subgroups with uncertain benefit from revascularization in endarterectomy trials.

View Article and Find Full Text PDF

Emerging evidence from randomized controlled clinical trials (RCTs) suggests that colchicine has cardiovascular benefits for patients with coronary disease, including benefits for stroke prevention. We performed an updated systematic review and meta-analysis of all RCTs reporting on stroke outcomes during the follow-up of patients with a history of cardiovascular disease randomized to colchicine treatment or control (placebo or usual care). We identified 6 RCTs including a total of 11,870 patients (mean age 63 years, 83% males) with a mean follow-up of 2 years.

View Article and Find Full Text PDF

Inflammation and Stroke Risk: A New Target for Prevention.

Stroke

August 2021

Second Department of Neurology, "Attikon" University Hospital, National & Kapodistrian University of Athens, Greece (G.T.).

New therapeutic approaches are required for secondary prevention of residual vascular risk after stroke. Diverse sources of evidence support a causal role for inflammation in the pathogenesis of stroke. Randomized controlled trials of anti-inflammatory agents have reported benefit for secondary prevention in patients with coronary disease.

View Article and Find Full Text PDF

Purpose: Inflammation is important in stroke. Anti-inflammatory therapy reduces vascular events in coronary patients. F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) identifies plaque inflammation-related metabolism.

View Article and Find Full Text PDF

Background And Purpose: Although clinical trials suggest that colchicine may reduce the risk of vascular events in patients with a history of coronary artery disease, its effect on the prevention of cerebrovascular events still remains unclear.

Methods: A systematic review and meta-analysis was performed of all available randomized controlled trials (RCTs) reporting on incident strokes during the follow-up of patients with a history of cardiovascular disease randomized to colchicine treatment or control (placebo or usual care).

Results: Four RCTs were identified, including a total of 5553 patients (mean age 61 years, 81% males), with a follow-up ranging from 1 to 36 months.

View Article and Find Full Text PDF